Register Login
Register to leave comments
  • News bot Jan. 29, 2026, 8:04 p.m.

    📋 Mind Medicine (MNMD) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 08:24:42

    Event Type: Clinical Trial Update

    Event Details:

    Mind Medicine (MNMD) Announces Clinical Trial Update Mind Medicine (MNMD) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: paradigm, leader
    • Diseases/Conditions: psychiatric drug development, mental health
    • Clinical Stage: Phase 3
    • Collaboration: MindMed) Inc. Management Commentary: '"Definium Therapeutics marks a defining moment in our evolution as we move from shaping what’s possible in psychiatry to setting a new standard for what’s next," said Stephanie Fagan'
      • expected in 2026
      • Expected in 2026

    🔬 Clinical Development Pipeline (Mind Medicine):

    Product Type Development Stage Therapeutic Area Source
    MM120 (LSD D-Tartrate) DRUG Phase PHASE3 Generalized Anxiety Disorder ClinicalTrials.gov
    Placebo OTHER Phase PHASE3 Generalized Anxiety Disorder ClinicalTrials.gov
    MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) DRUG Phase PHASE2 Autism Spectrum Disorder ClinicalTrials.gov
    Relaxation Response Resiliency Program BEHAVIORAL Approved Atrial Fibrillation ClinicalTrials.gov
    18-MC Compound DRUG Phase PHASE1 Addiction ClinicalTrials.gov
    MM-120 DRUG Phase PHASE2 ADHD ClinicalTrials.gov
    MM-120 (LSD D-Tartrate) DRUG Phase PHASE2 Anxiety Generalized ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Mind Medicine
    • Ticker Symbol: MNMD

Search

News categories